Activating mutations in ALK provide a therapeutic target in neuroblastoma
Activating mutations in ALK provide a therapeutic target in neuroblastoma
About this item
Full title
Author / Creator
George, Rani E. , Sanda, Takaomi , Hanna, Megan , Fröhling, Stefan , II, William Luther , Zhang, Jianming , Ahn, Yebin , Zhou, Wenjun , London, Wendy B. , McGrady, Patrick , Xue, Liquan , Zozulya, Sergey , Gregor, Vlad E. , Webb, Thomas R. , Gray, Nathanael S. , Gilliland, D. Gary , Diller, Lisa , Greulich, Heidi , Morris, Stephan W. , Meyerson, Matthew and Look, A. Thomas
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Neuroblastoma: a genetic link to ALK
Neuroblastoma is the most common childhood cancer. There is a strong familial association and it was predicted over 30 years ago that there was a genetic element to the disease. Four groups now report the identification of mutations in the tyrosine kinase receptor ALK (anaplastic lymphoma kinase) in neuroblas...
Alternative Titles
Full title
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Authors, Artists and Contributors
Author / Creator
Sanda, Takaomi
Hanna, Megan
Fröhling, Stefan
II, William Luther
Zhang, Jianming
Ahn, Yebin
Zhou, Wenjun
London, Wendy B.
McGrady, Patrick
Xue, Liquan
Zozulya, Sergey
Gregor, Vlad E.
Webb, Thomas R.
Gray, Nathanael S.
Gilliland, D. Gary
Diller, Lisa
Greulich, Heidi
Morris, Stephan W.
Meyerson, Matthew
Look, A. Thomas
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2587486
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2587486
Other Identifiers
ISSN
0028-0836
E-ISSN
1476-4687
DOI
10.1038/nature07397
